What is Lifesci Capital’s Forecast for Oculis Q2 Earnings?

Oculis Holding AG (NASDAQ:OCS) – Equities research analysts at Lifesci Capital upped their Q2 2026 earnings per share (EPS) estimates for Oculis in a note issued to investors on Tuesday, May 12th. Lifesci Capital analyst P. Dolezal now anticipates that the company will earn ($0.45) per share for the quarter, up from their previous estimate of ($0.47). The consensus estimate for Oculis’ current full-year earnings is ($2.17) per share. Lifesci Capital also issued estimates for Oculis’ Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.02) EPS.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The company had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%.

Several other analysts also recently issued reports on OCS. Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. HC Wainwright boosted their target price on shares of Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus boosted their target price on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Needham & Company LLC boosted their target price on shares of Oculis from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.14.

Oculis Price Performance

Shares of NASDAQ:OCS opened at $31.37 on Thursday. The company’s fifty day moving average is $27.25 and its two-hundred day moving average is $24.47. The company has a quick ratio of 5.96, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. Oculis has a 12-month low of $16.00 and a 12-month high of $34.47. The company has a market cap of $1.82 billion, a P/E ratio of -14.73 and a beta of 0.38.

Hedge Funds Weigh In On Oculis

Several institutional investors and hedge funds have recently modified their holdings of the stock. Himension Capital Singapore PTE. LTD. purchased a new position in shares of Oculis during the 1st quarter valued at $503,000. Koshinski Asset Management Inc. purchased a new position in shares of Oculis during the 1st quarter valued at $238,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Oculis during the 1st quarter valued at $776,000. Perceptive Advisors LLC purchased a new position in shares of Oculis during the 4th quarter valued at $9,862,000. Finally, Millennium Management LLC bought a new stake in Oculis in the fourth quarter worth $312,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis News Summary

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Needham raised its price target on Oculis to $46 from $40 and maintained a buy rating, implying meaningful upside from current levels. Oculis (NASDAQ:OCS) Price Target Raised to $46.00 at Needham & Company LLC
• Positive Sentiment: HC Wainwright increased its price target to $47 from $44 and kept a buy rating, while also slightly improving near-term earnings estimates. HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price
• Positive Sentiment: HC Wainwright and Lifesci Capital both nudged 2026 quarterly EPS estimates higher, suggesting analysts expect Oculis’ losses to be slightly smaller than previously projected.
• Neutral Sentiment: Lifesci Capital lowered its FY2026 EPS estimate to a loss of $2.02 per share, which still reflects continued unprofitability but is close to consensus.
• Negative Sentiment: Despite the estimate revisions, Oculis remains loss-making, and recent earnings history showed a wider-than-expected quarterly loss, which can limit the stock’s upside if execution disappoints.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.